Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Assets (2016 - 2025)

Historic Assets for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $868.8 million.

  • Amicus Therapeutics' Assets rose 1045.75% to $868.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $868.8 million, marking a year-over-year increase of 1045.75%. This contributed to the annual value of $785.0 million for FY2024, which is 91.96% up from last year.
  • Per Amicus Therapeutics' latest filing, its Assets stood at $868.8 million for Q3 2025, which was up 1045.75% from $815.3 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Assets peaked at $956.7 million during Q3 2021, and registered a low of $700.5 million during Q1 2023.
  • For the 5-year period, Amicus Therapeutics' Assets averaged around $792.6 million, with its median value being $786.6 million (2024).
  • Per our database at Business Quant, Amicus Therapeutics' Assets surged by 1218.06% in 2021 and then tumbled by 2060.75% in 2022.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Assets stood at $905.1 million in 2021, then dropped by 19.99% to $724.2 million in 2022, then increased by 7.42% to $777.9 million in 2023, then rose by 0.92% to $785.0 million in 2024, then rose by 10.67% to $868.8 million in 2025.
  • Its last three reported values are $868.8 million in Q3 2025, $815.3 million for Q2 2025, and $789.8 million during Q1 2025.